{
  "id": 3499200,
  "title": "H.C. Wainwright raises Zymeworks stock price target to $55 on FDA approval",
  "url": "https://urgent.news/2026/08/26/h-c-wainwright-raises-zymeworks-stock-price-target-to-55-on-fda",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-26T11:37:09.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-raises-zymeworks-stock-price-target-to-55-on-fda-approval-93CH-4876983"
  },
  "original_language": "en",
  "account": null,
  "summary": "H.C. Wainwright has increased its price target for Zymeworks stock (NASDAQ:ZYME) to $55 from $51, maintaining a Buy rating. The firm's decision is based on the FDA approval of Ziihera-containing regimens for first-line treatment of HER2-positive gastroesophageal adenocarcinoma. The approval is a significant milestone, triggering a $250 million payment from Jazz Pharmaceuticals, Zymeworks' partner. The FDA approval led to a 85% return for Zymeworks stock over the past year and positions the company near its 52-week high. Analysts predict the company will be profitable this year, with revenue growth forecast at 188% for FY2026.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}